Zurcher Kantonalbank Zurich Cantonalbank Buys 2,032 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 11.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,559 shares of the company’s stock after acquiring an additional 2,032 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in CRISPR Therapeutics were worth $1,287,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the stock. Cookson Peirce & Co. Inc. bought a new position in shares of CRISPR Therapeutics in the 4th quarter worth $389,000. Bourgeon Capital Management LLC raised its position in shares of CRISPR Therapeutics by 1,000.0% in the 4th quarter. Bourgeon Capital Management LLC now owns 550 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares in the last quarter. Granite Bay Wealth Management LLC raised its position in shares of CRISPR Therapeutics by 25.2% in the 4th quarter. Granite Bay Wealth Management LLC now owns 20,433 shares of the company’s stock worth $1,179,000 after acquiring an additional 4,116 shares in the last quarter. Capital Advisors Inc. OK raised its position in shares of CRISPR Therapeutics by 10.1% in the 4th quarter. Capital Advisors Inc. OK now owns 255,265 shares of the company’s stock worth $15,980,000 after acquiring an additional 23,340 shares in the last quarter. Finally, Perigon Wealth Management LLC increased its position in CRISPR Therapeutics by 4.3% during the 4th quarter. Perigon Wealth Management LLC now owns 14,918 shares of the company’s stock valued at $934,000 after buying an additional 609 shares in the last quarter. 69.20% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on CRSP shares. Morgan Stanley upped their target price on CRISPR Therapeutics from $46.00 to $48.00 and gave the company an “underweight” rating in a research report on Monday, February 26th. Wells Fargo & Company upped their target price on CRISPR Therapeutics from $55.00 to $70.00 and gave the company an “equal weight” rating in a research report on Thursday, February 22nd. Barclays upped their target price on CRISPR Therapeutics from $61.00 to $80.00 and gave the company an “equal weight” rating in a research report on Thursday, February 22nd. Mizuho upped their target price on CRISPR Therapeutics from $82.00 to $99.00 and gave the company a “buy” rating in a research report on Wednesday, March 6th. Finally, Royal Bank of Canada increased their price objective on CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a report on Thursday, February 22nd. Three analysts have rated the stock with a sell rating, six have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $76.29.

CRISPR Therapeutics Stock Up 0.3 %

Shares of CRSP opened at $53.91 on Friday. CRISPR Therapeutics AG has a 52 week low of $37.55 and a 52 week high of $91.10. The company has a market capitalization of $4.58 billion, a price-to-earnings ratio of -27.50 and a beta of 1.76. The stock’s 50-day moving average price is $70.57 and its 200-day moving average price is $63.81.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, topping analysts’ consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million during the quarter, compared to analysts’ expectations of $148.72 million. During the same quarter in the previous year, the company earned ($1.41) EPS. The firm’s quarterly revenue was up 3253.3% compared to the same quarter last year. As a group, equities analysts anticipate that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,000 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $60.51, for a total transaction of $3,025,500.00. Following the transaction, the chief executive officer now owns 187,377 shares in the company, valued at $11,338,182.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 50,000 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $60.51, for a total transaction of $3,025,500.00. Following the transaction, the chief executive officer now owns 187,377 shares in the company, valued at $11,338,182.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Raju Prasad sold 3,524 shares of the stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $72.69, for a total value of $256,159.56. Following the transaction, the chief financial officer now owns 6,476 shares in the company, valued at approximately $470,740.44. The disclosure for this sale can be found here. Insiders have sold 133,992 shares of company stock worth $9,157,835 over the last quarter. 4.10% of the stock is currently owned by insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.